Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature

Endocrine

Volumn 37, Issue 1, 2010, Pages 6-10

  Kaldrymides, Ph ^a   Kostoglou Athanassiou, I ^a   Gkountouvas, A ^a   Veniou, E ^a   Ziras, N ^a  

^a METAXA CANCER HOSPITAL   (Greece)

Author keywords

Metastatic thyroid carcinoma; Papillary thyroid cancer; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

CARBIMAZOLE; IODINE 131; SUNITINIB; THYROGLOBULIN;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD CELL COUNT; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG MONITORING; HUMAN; HYPERTHYROIDISM; LIVER FUNCTION TEST; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; THYROGLOBULIN BLOOD LEVEL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

EID: 75949103344     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-009-9290-z     Document Type: Article

References (44)

1. A Jemal T Murray E Ward A Samuels RC Tiwari A Ghafoor EJ Feuer MJ Thun 2005 Cancer statistics, 2005 CA Cancer J. Clin. 55 10 30 10.3322/canjclin.55.1. 10 15661684
2. L Davies JG Welch 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002 JAMA 295 2164 2167 10.1001/jama.295.18.2164 1:CAS:528:DC%2BD28XksV2gtLg%3D 16684987
3. DS Cooper GM Doherty BR Haugen RT Kloos SL Lee SJ Mandel EL Mazzaferri B McIver SI Sherman RM Tuttle The American Thyroid Association Guidelines Taskforce 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 16 109 142 10.1089/thy.2006.16.109 16420177
4. BR Haugen 1999 Management of the patient with progressive radioiodine non-responsive disease Semin. Surg. Oncol. 16 34 41 10.1002/(SICI)1098- 2388(199901/02)16:1<34::AID-SSU7>3.0.CO;2-2 1:STN:280:DyaK1M7gsFOntg%3D%3D 9890738
5. K Shimaoka D Schoenfeld WD DeWys RH Greech R DeConti 1985 A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma Cancer 56 2155 2160 10.1002/1097-0142(19851101)56:9<2155:: AID-CNCR2820560903>3.0.CO;2-E 1:STN:280:DyaL28%2FislOjtw%3D%3D 3902203 (Pubitemid 16236586)
6. P De Besi B Busnardo S Toso ME Girelli D Nacamulli N Simioni D Casara P Zorat MV Fiorentino 1991 Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer J. Endocrinol. Invest. 14 475 480 1723086
7. T Kondo S Ezzat SL Asa 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia Nat. Rev. Cancer 6 292 306 10.1038/nrc1836 1:CAS:528:DC%2BD28XivVyqsbg%3D 16557281
8. M Santoro F Carlomagno 2006 Drug insight: small-molecule inhibitors of protein kinases in the treatment of thyroid cancer Natl Clin. Pract. Endocrinol. Metab. 2 42 52 10.1038/ncpendmet0073 1:CAS:528:DC%2BD28Xis1Sitrs%3D
9. MD Castellone F Carlomagno G Salvatore M Santoro 2008 Receptor tyrosine kinase inhibitors in thyroid cancer Best Pract. Res. Clin. Endocrinol. Metab. 22 1023 1038 10.1016/j.beem.2008.09.012 1:CAS:528:DC%2BD1cXhsVeksrbI 19041829
10. JA Fagin 2004 How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy J. Endocrinol. 183 249 256 10.1677/joe.1.05895 1:CAS:528:DC%2BD2cXhtVGlsbvM 15531713 (Pubitemid 39562707)
11. S Trovisco P Soares M Sobrinho-Simoes 2006 B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas Human Pathol. 37 781 786 10.1016/j.humpath.2006.03.013 1:CAS:528:DC%2BD28XlvFGms7Y%3D (Pubitemid 43902956)
12. RL Brown C Ezra 2008 Tyrosine kinase inhibition: novel treatment for advanced thyroid cancer Rev. Endocrinol. 8 21 24
13. DW Kim YS Jo HS Jung HK Chung JH Song KC Park SH Park JH Hwang SY Rha GR Kweon SJ Lee KW Jo M Shong 2006 An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases J. Clin. Endocrinol. Metab. 91 4070 4076 10.1210/jc.2005-2845 1:CAS:528:DC%2BD28XhtFSjtbrN 16849418 (Pubitemid 44536887)
14. TM de Reijke J Bellmunt H van Poppel S Marreaud M Aapro 2009 EORTC-GU group expert opinion on metastatic renal cell cancer Eur. J. Cancer 45 765 773 10.1016/j.ejca.2008.12.010 19157861
15. Anonymous, Sunitinib: new drug. For some gastrointestinal stromal tumours. Prescribe Int. 16, 138-141 (2007)
16. DR Robinson YM Wu SF Lin 2000 The protein tyrosine kinase family of the human genome Oncogene 19 5548 5557 10.1038/sj.onc.1203957 1:CAS:528: DC%2BD3cXosl2ntbs%3D 11114734
17. E Zwick J Bange A Ullrich 2001 Receptor tyrosine kinase signalling as a target for cancer intervention strategies Endocr. Relat. Cancer 8 161 173 10.1677/erc.0.0080161 1:CAS:528:DC%2BD3MXotlCqsL0%3D 11566607 (Pubitemid 32947638)
18. RH Gunby E Sala CJ Tartari M Puttini C Gambacorti-Passerini L Mologni 2007 Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy AntiCancer Agents Med. Chem. 7 594 611 10.2174/187152007784111340 1:CAS:528:DC%2BD2sXhtlWiur%2FO 18045055 (Pubitemid 350237765)
19. P Soares V Trovisco AS Rocha J Lima P Castro A Preto V Máximo T Botelho R Seruca M Sobrinho-Simões 2003 BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC Oncogene 22 4578 4580 10.1038/sj.onc.1206706 1:CAS:528:DC%2BD3sXls1yntL0%3D 12881714 (Pubitemid 36920701)
20. DG Pfister JA Fagin 2008 Refractory thyroid cancer: a paradigm shift in treatment is not far off J. Clin. Oncol. 26 4701 4704 10.1200/JCO.2008.17.3682 1:CAS:528:DC%2BD1cXhtlSqsLfL 18541893
21. M Santoro RM Melillo F Carlomagno A Fusco G Vecchio 2002 Molecular mechanisms of RET activation in human cancer Ann. NY Acad. Sci. 963 116 121 1:CAS:528:DC%2BD38XlvVOju7g%3D 12095936
22. M Grieco M Santoro MT Berlingieri RM Melillo R Donghi I Borganzone MA Pierotti G Della Porta A Fusco G Vecchio 1990 PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas Cell 60 557 563 10.1016/0092-8674(90)90659-3 1:CAS:528:DyaK3cXhsFaqt74%3D 2406025 (Pubitemid 20083812)
23. E Baudin M Schlumberger 2007 New therapeutic approaches for metastatic thyroid carcinoma Lancet Oncol. 8 148 156 10.1016/S1470-2045(07)70034-7 1:CAS:528:DC%2BD2sXhtlSgtLg%3D 17267329 (Pubitemid 46158381)
24. P Kundra KD Burman 2007 Thyroid cancer molecular signaling pathways and use of targeted therapy Endocrinol. Metab. Clin. North Am. 36 839 853 10.1016/j.ecl.2007.06.001 1:CAS:528:DC%2BD2sXhtFCgsrjI 17673131 (Pubitemid 47126259)
25. SM Coehlo DP de Carvahlo M Vaisman 2007 New perspectives on the treatment of differentiated thyroid cancer Arq. Bras. Endocrinol. Metab. 51 612 624
26. G Malouf E Baudin JC Soria M Schlumberger 2009 Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies Bull. Cancer 96 95 101 1:CAS:528:DC%2BD1MXjtlSjtL4%3D 19211364
27. SI Sherman 2009 Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers J. Clin. Endocrinol. Metab. 94 1493 1499 10.1210/jc.2008-0923 1:CAS:528:DC%2BD1MXlvVCqsbs%3D 19258410
28. JK Smith NM Mamoun RJ Duhe 2004 Emerging roles of targeted small molecule protein-kinase inhibitors in cancer therapy Oncol. Res. 14 175 225 14977353
29. C Lanzi G Cassinelli T Pensa M Cassinis RA Gambetta MG Borrello E Menta MA Pierrotti F Zunino 2000 Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative Int. J. Cancer 85 384 390 10.1002/(SICI)1097-0215(20000201)85:3<384::AID-IJC15>3.0.CO;2-Y 1:CAS:528:DC%2BD3cXmsVCgtA%3D%3D 10652431 (Pubitemid 30030413)
30. DB Mendel AD Laird X Xin SG Louie JG Christensen G Li RE Schreck TJ Abrams TJ Ngai LB Lee LJ Murray J Carver E Chan KG Moss JO Haznedar J Sukbuntherng RA Blake L Sun C Tang T Miller S Shirazian G McMahon JM Cherrington 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin. Cancer Res. 9 327 337 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D 12538485 (Pubitemid 36109749)
31. LQ Chow SG Eckhardt 2007 Sunitinib: from rational design to clinical efficacy J. Clin. Oncol. 25 884 896 10.1200/JCO.2006.06.3602 1:CAS:528:DC%2BD2sXjvVKmtLY%3D 17327610 (Pubitemid 350002890)
32. P Wolter C Stefan B Decallonne H Dumez M Bex P Carmeliet P Schöffski 2008 The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation Br. J. Cancer 99 448 454 10.1038/sj.bjc.6604497 1:CAS:528:DC%2BD1cXptFSnsbc%3D 18665181
33. R Cohen H Bihan B Uzzan G des Guetz A Krivitzky 2007 Sunitinib and hypothyroidism Ann. Endocrinol. (Paris) 68 332 336 1:CAS:528: DC%2BD1cXnsFOltA%3D%3D
34. BI Rini I Tamaskar P Shaheen R Salas J Garcia L Wood S Reddy R Dreicer RM Bukowski 2007 Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib J. Natl Cancer Inst. 99 81 83 1:CAS:528: DC%2BD2sXhs1Wnur4%3D 17202116
35. M Grossmann E Premaratne J Desai ID Davis 2008 Thyrotoxicosis during sunitinib treatment for renal cell carcinoma Clin. Endocrinol. (Oxf) 69 669 672 10.1111/j.1365-2265.2008.03253.x 1:CAS:528:DC%2BD1cXht1KqtLnK
36. JE Faris AF Moore GH Daniels 2007 Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report Thyroid 17 1147 1149 10.1089/thy.2007.0104 17714037 (Pubitemid 350207759)
37. E Wong LS Rosen M Mulay A Vanvugt M Dinolfo C Tomoda M Sugawara JM Hershman 2007 Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity Thyroid 17 351 355 10.1089/thy.2006.0308 1:CAS:528:DC%2BD2sXkslClur4%3D 17465866 (Pubitemid 46776140)
38. EA Eisenhauer P Therasse J Bogaerts LH Schwartz D Sargent R Ford J Dancey S Arbuck S Gwyther M Mooney L Rubinstein L Shankar L Dodd R Kaplan D Lacombe J Verweij 2009 New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur. J. Cancer 45 228 247 10.1016/j.ejca.2008.10.026 1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D 19097774
39. SJ Dawson NM Conus GC Toner JM Raleigh RJ Hicks G McArthur D Rischin 2008 Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma Anticancer Drugs 19 547 552 1:CAS:528:DC%2BD1cXks12gsL0%3D 18418222
40. EE Cohen BM Needles KJ Cullen SJ Wong JL Wade SP Ivy VM Villaflor TY Seiwert K Nichols EE Vokes 2008 Phase 2 study of sunitinib in refractory thyroid cancer J. Clin. Oncol. 26 suppl 6025 (abstr)
41. A Ravaud C de la Fouchardière F Courbon J Asselineau M Klein P Nicoli-Sire C Bournaud J Delord G Weryha B Catargi 2008 Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial J. Clin. Oncol. 26 suppl 6058 (abstr)
42. FC Kelleher R McDermott 2008 Response to sunitinib in medullary thyroid cancer Ann. Intern. Med. 148 567 18378960
43. MJ Bugalho R Domingues A Borges 2009 Case report: a case of advanced medullary thyroid carcinoma successfully treated with sunitinib Oncologist 14 1083 1087 10.1634/theoncologist.2009-0195 19887470
44. N Steeghs JW Nortier H Gelderblom 2007 Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments Ann. Surg. Oncol. 14 942 953 10.1245/s10434-006-9227-1 17103252 (Pubitemid 46175346)